Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Thyroid Neoplasms | 74 | 2023 | 408 | 12.030 |
Why?
|
Informed Consent | 32 | 2023 | 266 | 9.060 |
Why?
|
Thyroidectomy | 51 | 2023 | 170 | 8.420 |
Why?
|
Surgeons | 20 | 2023 | 238 | 7.570 |
Why?
|
Surgical Procedures, Operative | 23 | 2022 | 182 | 7.540 |
Why?
|
Ethics, Medical | 28 | 2023 | 306 | 6.550 |
Why?
|
General Surgery | 20 | 2021 | 229 | 5.110 |
Why?
|
Physician-Patient Relations | 23 | 2023 | 610 | 4.860 |
Why?
|
Parathyroidectomy | 26 | 2024 | 78 | 4.610 |
Why?
|
Pneumonia, Viral | 11 | 2020 | 316 | 3.740 |
Why?
|
Coronavirus Infections | 11 | 2020 | 301 | 3.730 |
Why?
|
Decision Making | 15 | 2023 | 642 | 3.270 |
Why?
|
Humans | 263 | 2024 | 86643 | 2.830 |
Why?
|
Thyroid Nodule | 12 | 2022 | 51 | 2.750 |
Why?
|
Recurrent Laryngeal Nerve Injuries | 10 | 2022 | 17 | 2.720 |
Why?
|
Surgery Department, Hospital | 5 | 2020 | 42 | 2.570 |
Why?
|
Carcinoma, Papillary | 18 | 2021 | 158 | 2.490 |
Why?
|
Ethics, Research | 7 | 2018 | 52 | 2.490 |
Why?
|
Hyperparathyroidism, Primary | 11 | 2021 | 41 | 2.310 |
Why?
|
Specialties, Surgical | 7 | 2021 | 64 | 2.110 |
Why?
|
Clinical Trials as Topic | 8 | 2020 | 1169 | 2.010 |
Why?
|
Thyroid Diseases | 11 | 2020 | 104 | 1.960 |
Why?
|
Monitoring, Intraoperative | 9 | 2022 | 109 | 1.890 |
Why?
|
Pandemics | 11 | 2020 | 740 | 1.860 |
Why?
|
Incidental Findings | 6 | 2016 | 95 | 1.810 |
Why?
|
Postoperative Complications | 21 | 2020 | 2207 | 1.740 |
Why?
|
Thyroid Gland | 16 | 2023 | 270 | 1.720 |
Why?
|
Parathyroid Neoplasms | 10 | 2016 | 55 | 1.670 |
Why?
|
Patient Selection | 10 | 2020 | 685 | 1.620 |
Why?
|
Betacoronavirus | 10 | 2020 | 258 | 1.590 |
Why?
|
Truth Disclosure | 7 | 2015 | 87 | 1.580 |
Why?
|
Ethics, Clinical | 5 | 2023 | 48 | 1.550 |
Why?
|
Operating Rooms | 3 | 2022 | 126 | 1.500 |
Why?
|
Preoperative Care | 10 | 2023 | 397 | 1.450 |
Why?
|
Patient Participation | 4 | 2021 | 216 | 1.410 |
Why?
|
Diffusion of Innovation | 3 | 2021 | 71 | 1.390 |
Why?
|
Physicians | 7 | 2023 | 673 | 1.380 |
Why?
|
Hyperparathyroidism, Secondary | 5 | 2024 | 70 | 1.360 |
Why?
|
Quality Improvement | 5 | 2022 | 428 | 1.360 |
Why?
|
Parathyroid Hormone | 13 | 2024 | 218 | 1.300 |
Why?
|
Endocrinology | 10 | 2021 | 66 | 1.300 |
Why?
|
Robotic Surgical Procedures | 5 | 2020 | 267 | 1.270 |
Why?
|
Tissue and Organ Procurement | 6 | 2022 | 311 | 1.270 |
Why?
|
Elective Surgical Procedures | 5 | 2020 | 116 | 1.270 |
Why?
|
Physician's Role | 6 | 2020 | 179 | 1.230 |
Why?
|
Watchful Waiting | 3 | 2017 | 60 | 1.220 |
Why?
|
Internship and Residency | 5 | 2023 | 1004 | 1.200 |
Why?
|
Vocal Cord Paralysis | 8 | 2021 | 26 | 1.160 |
Why?
|
Intraoperative Complications | 7 | 2018 | 185 | 1.150 |
Why?
|
Organ Transplantation | 5 | 2017 | 265 | 1.140 |
Why?
|
Postoperative Care | 5 | 2020 | 221 | 1.140 |
Why?
|
Delivery of Health Care | 2 | 2021 | 426 | 1.090 |
Why?
|
Inventions | 3 | 2016 | 13 | 1.090 |
Why?
|
Genomics | 3 | 2023 | 720 | 1.080 |
Why?
|
Biomedical Research | 6 | 2014 | 376 | 1.070 |
Why?
|
Technetium Tc 99m Sestamibi | 5 | 2019 | 15 | 1.060 |
Why?
|
Clinical Decision-Making | 4 | 2017 | 257 | 1.060 |
Why?
|
Communication | 8 | 2020 | 441 | 1.060 |
Why?
|
United States | 42 | 2021 | 6672 | 1.060 |
Why?
|
Adenoma | 9 | 2015 | 235 | 1.040 |
Why?
|
Advance Directives | 7 | 2013 | 64 | 1.000 |
Why?
|
Parathyroid Diseases | 3 | 2009 | 9 | 0.990 |
Why?
|
Risk Assessment | 14 | 2023 | 2261 | 0.990 |
Why?
|
Living Donors | 6 | 2013 | 339 | 0.990 |
Why?
|
Hashimoto Disease | 2 | 2023 | 10 | 0.980 |
Why?
|
Patient Preference | 2 | 2016 | 105 | 0.970 |
Why?
|
Radiopharmaceuticals | 5 | 2019 | 180 | 0.960 |
Why?
|
Adenocarcinoma, Follicular | 7 | 2017 | 51 | 0.960 |
Why?
|
Terminology as Topic | 2 | 2015 | 217 | 0.950 |
Why?
|
Medical Errors | 4 | 2016 | 115 | 0.950 |
Why?
|
Attitude of Health Personnel | 10 | 2020 | 636 | 0.940 |
Why?
|
Cultural Diversity | 3 | 2021 | 51 | 0.940 |
Why?
|
Bioethics | 2 | 2023 | 35 | 0.910 |
Why?
|
Morals | 2 | 2021 | 92 | 0.910 |
Why?
|
Disclosure | 2 | 2021 | 108 | 0.910 |
Why?
|
Recurrent Laryngeal Nerve | 6 | 2021 | 11 | 0.900 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2023 | 28 | 0.900 |
Why?
|
Ownership | 2 | 2022 | 26 | 0.880 |
Why?
|
Adrenal Gland Neoplasms | 6 | 2016 | 80 | 0.870 |
Why?
|
Leadership | 3 | 2021 | 134 | 0.860 |
Why?
|
Parathyroid Glands | 8 | 2024 | 74 | 0.860 |
Why?
|
Quality of Life | 8 | 2022 | 1585 | 0.850 |
Why?
|
Female | 79 | 2021 | 44532 | 0.840 |
Why?
|
Anemia | 1 | 2023 | 128 | 0.830 |
Why?
|
Resuscitation Orders | 1 | 2022 | 62 | 0.820 |
Why?
|
Neck Dissection | 8 | 2021 | 65 | 0.820 |
Why?
|
Stakeholder Participation | 1 | 2021 | 19 | 0.810 |
Why?
|
Health Care Costs | 4 | 2020 | 238 | 0.810 |
Why?
|
Conscience | 1 | 2021 | 20 | 0.800 |
Why?
|
Hypocalcemia | 6 | 2024 | 41 | 0.800 |
Why?
|
Burnout, Professional | 2 | 2022 | 94 | 0.790 |
Why?
|
Tape Recording | 1 | 2021 | 19 | 0.790 |
Why?
|
Faculty, Medical | 2 | 2020 | 178 | 0.790 |
Why?
|
Robotics | 2 | 2016 | 267 | 0.790 |
Why?
|
Videotape Recording | 1 | 2021 | 47 | 0.780 |
Why?
|
Pathology | 2 | 2013 | 30 | 0.770 |
Why?
|
Smartphone | 1 | 2021 | 36 | 0.770 |
Why?
|
Patient Comfort | 1 | 2020 | 7 | 0.760 |
Why?
|
Self Disclosure | 1 | 2020 | 31 | 0.750 |
Why?
|
Survivors | 3 | 2016 | 226 | 0.730 |
Why?
|
Coronavirus | 1 | 2020 | 19 | 0.730 |
Why?
|
Retrospective Studies | 34 | 2022 | 8489 | 0.730 |
Why?
|
Hormone Replacement Therapy | 1 | 2020 | 77 | 0.710 |
Why?
|
Motivation | 2 | 2021 | 287 | 0.700 |
Why?
|
Professional-Family Relations | 3 | 2014 | 48 | 0.700 |
Why?
|
Healthcare Disparities | 3 | 2023 | 371 | 0.690 |
Why?
|
Male | 72 | 2021 | 40965 | 0.690 |
Why?
|
Practice Patterns, Physicians' | 5 | 2017 | 582 | 0.690 |
Why?
|
Calcium | 10 | 2024 | 1156 | 0.680 |
Why?
|
Sexual Harassment | 1 | 2019 | 9 | 0.680 |
Why?
|
Biopsy, Fine-Needle | 10 | 2022 | 93 | 0.670 |
Why?
|
Hypoparathyroidism | 3 | 2024 | 22 | 0.660 |
Why?
|
Health Equity | 1 | 2020 | 77 | 0.650 |
Why?
|
Suicide | 1 | 2020 | 139 | 0.650 |
Why?
|
Human Experimentation | 4 | 2013 | 39 | 0.650 |
Why?
|
Sexism | 1 | 2019 | 51 | 0.650 |
Why?
|
Life Support Care | 2 | 2012 | 49 | 0.640 |
Why?
|
Physicians, Women | 1 | 2019 | 53 | 0.640 |
Why?
|
Emergency Treatment | 1 | 2018 | 39 | 0.640 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 454 | 0.630 |
Why?
|
Clinical Competence | 6 | 2016 | 751 | 0.630 |
Why?
|
Disease Management | 4 | 2017 | 327 | 0.630 |
Why?
|
Counseling | 2 | 2016 | 145 | 0.630 |
Why?
|
Patient Satisfaction | 2 | 2020 | 455 | 0.610 |
Why?
|
Middle Aged | 51 | 2021 | 25028 | 0.610 |
Why?
|
Medical Futility | 3 | 2010 | 28 | 0.610 |
Why?
|
Neoplasms | 7 | 2016 | 2898 | 0.610 |
Why?
|
Kidney Failure, Chronic | 2 | 2014 | 509 | 0.600 |
Why?
|
Pheochromocytoma | 3 | 2010 | 49 | 0.590 |
Why?
|
Patient Safety | 2 | 2016 | 212 | 0.580 |
Why?
|
Research Subjects | 3 | 2014 | 73 | 0.580 |
Why?
|
Cysts | 2 | 2008 | 104 | 0.580 |
Why?
|
Emergency Medicine | 1 | 2018 | 123 | 0.570 |
Why?
|
Palliative Care | 6 | 2013 | 257 | 0.570 |
Why?
|
Hypercalcemia | 3 | 2021 | 59 | 0.560 |
Why?
|
Laryngeal Nerve Injuries | 2 | 2015 | 3 | 0.560 |
Why?
|
Moral Obligations | 3 | 2012 | 52 | 0.550 |
Why?
|
Patient Care | 2 | 2023 | 100 | 0.550 |
Why?
|
Personal Autonomy | 3 | 2015 | 112 | 0.550 |
Why?
|
Patient Education as Topic | 3 | 2015 | 351 | 0.550 |
Why?
|
Prognosis | 17 | 2023 | 3679 | 0.540 |
Why?
|
Adult | 48 | 2021 | 25648 | 0.540 |
Why?
|
Interprofessional Relations | 1 | 2016 | 121 | 0.540 |
Why?
|
Genetic Testing | 2 | 2023 | 535 | 0.540 |
Why?
|
Intraoperative Care | 1 | 2016 | 82 | 0.530 |
Why?
|
Laryngeal Nerves | 1 | 2015 | 3 | 0.530 |
Why?
|
Conflict of Interest | 4 | 2014 | 67 | 0.530 |
Why?
|
Withholding Treatment | 3 | 2013 | 112 | 0.510 |
Why?
|
Patient Care Planning | 1 | 2015 | 81 | 0.510 |
Why?
|
Carcinoma | 5 | 2018 | 436 | 0.510 |
Why?
|
Hyperostosis Frontalis Interna | 1 | 2014 | 5 | 0.510 |
Why?
|
Infection Control | 3 | 2020 | 115 | 0.510 |
Why?
|
Cardiac Surgical Procedures | 1 | 2019 | 462 | 0.500 |
Why?
|
Critical Illness | 2 | 2015 | 294 | 0.500 |
Why?
|
Carcinoma, Lobular | 1 | 2015 | 81 | 0.500 |
Why?
|
Interpersonal Relations | 2 | 2015 | 170 | 0.500 |
Why?
|
Cognition Disorders | 1 | 2016 | 236 | 0.500 |
Why?
|
Thymectomy | 2 | 2014 | 31 | 0.490 |
Why?
|
Video-Assisted Surgery | 3 | 2015 | 6 | 0.490 |
Why?
|
Monitoring, Physiologic | 2 | 2009 | 268 | 0.490 |
Why?
|
Curriculum | 4 | 2023 | 539 | 0.490 |
Why?
|
Pancreatic Neoplasms | 6 | 2020 | 645 | 0.490 |
Why?
|
Guidelines as Topic | 2 | 2013 | 162 | 0.480 |
Why?
|
Minimally Invasive Surgical Procedures | 9 | 2019 | 237 | 0.480 |
Why?
|
Neoplasms, Radiation-Induced | 2 | 2016 | 109 | 0.480 |
Why?
|
Intestines | 2 | 2009 | 411 | 0.480 |
Why?
|
Iodine Radioisotopes | 4 | 2021 | 134 | 0.480 |
Why?
|
Lymphatic Metastasis | 11 | 2021 | 486 | 0.470 |
Why?
|
Cohort Studies | 10 | 2022 | 2767 | 0.470 |
Why?
|
Mastectomy | 1 | 2015 | 243 | 0.450 |
Why?
|
Patient-Centered Care | 2 | 2016 | 203 | 0.450 |
Why?
|
Graves Disease | 2 | 2013 | 36 | 0.440 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 252 | 0.440 |
Why?
|
Thyroid Carcinoma, Anaplastic | 2 | 2022 | 13 | 0.440 |
Why?
|
Consensus | 8 | 2023 | 335 | 0.430 |
Why?
|
Larynx | 3 | 2021 | 38 | 0.430 |
Why?
|
Laparoscopy | 4 | 2011 | 754 | 0.430 |
Why?
|
Academic Medical Centers | 5 | 2021 | 379 | 0.430 |
Why?
|
Cranial Nerve Injuries | 1 | 2012 | 3 | 0.420 |
Why?
|
Coercion | 1 | 2012 | 15 | 0.420 |
Why?
|
Critical Care | 1 | 2015 | 370 | 0.420 |
Why?
|
Evidence-Based Medicine | 4 | 2020 | 429 | 0.410 |
Why?
|
Cognition | 1 | 2016 | 570 | 0.410 |
Why?
|
Intensive Care Units | 1 | 2015 | 373 | 0.410 |
Why?
|
Social Responsibility | 4 | 2016 | 57 | 0.410 |
Why?
|
Surgery, Plastic | 1 | 2012 | 42 | 0.410 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2021 | 1313 | 0.410 |
Why?
|
Vascular System Injuries | 1 | 2011 | 29 | 0.400 |
Why?
|
Axilla | 1 | 2011 | 99 | 0.400 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2023 | 865 | 0.400 |
Why?
|
Practice Guidelines as Topic | 7 | 2020 | 1036 | 0.380 |
Why?
|
Medical Oncology | 1 | 2014 | 359 | 0.380 |
Why?
|
Intraoperative Neurophysiological Monitoring | 3 | 2018 | 9 | 0.380 |
Why?
|
Professional Autonomy | 2 | 2015 | 41 | 0.380 |
Why?
|
Patient Care Team | 3 | 2022 | 280 | 0.380 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2022 | 138 | 0.380 |
Why?
|
Confidentiality | 3 | 2021 | 78 | 0.370 |
Why?
|
Medical Tourism | 1 | 2010 | 5 | 0.370 |
Why?
|
Malpractice | 1 | 2010 | 57 | 0.370 |
Why?
|
Commerce | 1 | 2010 | 29 | 0.360 |
Why?
|
Placebos | 2 | 2017 | 218 | 0.360 |
Why?
|
Carcinoma, Papillary, Follicular | 2 | 2020 | 13 | 0.360 |
Why?
|
Struma Ovarii | 1 | 2009 | 1 | 0.350 |
Why?
|
Program Development | 1 | 2010 | 124 | 0.350 |
Why?
|
Natural Orifice Endoscopic Surgery | 2 | 2020 | 38 | 0.350 |
Why?
|
Beneficence | 4 | 2015 | 33 | 0.340 |
Why?
|
Adenocarcinoma | 3 | 2022 | 1169 | 0.340 |
Why?
|
Aged | 28 | 2023 | 18415 | 0.340 |
Why?
|
Incidence | 11 | 2019 | 1577 | 0.330 |
Why?
|
Adrenocortical Carcinoma | 1 | 2008 | 12 | 0.330 |
Why?
|
Adenoma, Oxyphilic | 4 | 2021 | 28 | 0.330 |
Why?
|
Surveys and Questionnaires | 6 | 2022 | 2501 | 0.320 |
Why?
|
Neurosurgery | 1 | 2009 | 84 | 0.310 |
Why?
|
Ultrasonography | 7 | 2019 | 695 | 0.310 |
Why?
|
Multiple Endocrine Neoplasia | 2 | 2006 | 7 | 0.310 |
Why?
|
Treatment Outcome | 14 | 2021 | 7993 | 0.300 |
Why?
|
Ischemia | 1 | 2009 | 243 | 0.300 |
Why?
|
Educational Status | 3 | 2023 | 188 | 0.300 |
Why?
|
Neoplasm Staging | 9 | 2020 | 1939 | 0.300 |
Why?
|
Head and Neck Neoplasms | 3 | 2023 | 1052 | 0.300 |
Why?
|
Capitation Fee | 1 | 2006 | 2 | 0.300 |
Why?
|
Vena Cava, Inferior | 1 | 2008 | 143 | 0.290 |
Why?
|
Societies, Medical | 9 | 2020 | 572 | 0.290 |
Why?
|
Internationality | 2 | 2021 | 69 | 0.290 |
Why?
|
Diagnostic Errors | 1 | 2008 | 160 | 0.290 |
Why?
|
Therapies, Investigational | 3 | 2019 | 17 | 0.290 |
Why?
|
Guideline Adherence | 3 | 2018 | 223 | 0.290 |
Why?
|
Risk Factors | 13 | 2021 | 5417 | 0.280 |
Why?
|
Cancer Survivors | 2 | 2018 | 85 | 0.280 |
Why?
|
Neuroendocrine Tumors | 2 | 2020 | 105 | 0.280 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 92 | 0.280 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2005 | 6 | 0.280 |
Why?
|
Social Behavior | 2 | 2021 | 294 | 0.280 |
Why?
|
Stress, Psychological | 3 | 2020 | 313 | 0.280 |
Why?
|
Neoplasm Metastasis | 2 | 2015 | 1056 | 0.270 |
Why?
|
Thyroiditis | 2 | 2023 | 10 | 0.270 |
Why?
|
History, 20th Century | 3 | 2014 | 312 | 0.270 |
Why?
|
Treatment Refusal | 3 | 2020 | 60 | 0.270 |
Why?
|
Neoplasm Invasiveness | 5 | 2021 | 552 | 0.270 |
Why?
|
Risk | 4 | 2020 | 674 | 0.270 |
Why?
|
Multiple Myeloma | 1 | 2009 | 307 | 0.260 |
Why?
|
Rare Diseases | 2 | 2016 | 59 | 0.260 |
Why?
|
Survival Rate | 8 | 2016 | 1863 | 0.260 |
Why?
|
Precision Medicine | 3 | 2022 | 395 | 0.260 |
Why?
|
Professional Misconduct | 2 | 2022 | 25 | 0.260 |
Why?
|
Breast Neoplasms | 2 | 2016 | 2903 | 0.260 |
Why?
|
Patient Self-Determination Act | 2 | 2008 | 4 | 0.250 |
Why?
|
Intestinal Neoplasms | 2 | 2020 | 56 | 0.250 |
Why?
|
History, 19th Century | 3 | 2017 | 59 | 0.250 |
Why?
|
Organizational Culture | 3 | 2019 | 33 | 0.250 |
Why?
|
Education, Medical, Graduate | 2 | 2005 | 369 | 0.240 |
Why?
|
Judgment | 2 | 2018 | 64 | 0.240 |
Why?
|
History, 21st Century | 3 | 2021 | 175 | 0.240 |
Why?
|
Proto-Oncogene Proteins c-ret | 1 | 2023 | 21 | 0.240 |
Why?
|
Lymph Nodes | 5 | 2021 | 533 | 0.240 |
Why?
|
Consensus Development Conferences as Topic | 2 | 2021 | 28 | 0.230 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 30 | 0.230 |
Why?
|
Personal Protective Equipment | 2 | 2020 | 32 | 0.230 |
Why?
|
Total Quality Management | 1 | 2003 | 34 | 0.230 |
Why?
|
Severity of Illness Index | 4 | 2016 | 1801 | 0.230 |
Why?
|
Terminal Care | 3 | 2013 | 130 | 0.220 |
Why?
|
Personnel Selection | 2 | 2018 | 59 | 0.220 |
Why?
|
Adrenalectomy | 1 | 2002 | 43 | 0.220 |
Why?
|
Triage | 2 | 2020 | 108 | 0.220 |
Why?
|
Disease Progression | 3 | 2017 | 1531 | 0.220 |
Why?
|
Early Detection of Cancer | 2 | 2017 | 394 | 0.220 |
Why?
|
Professionalism | 1 | 2022 | 24 | 0.210 |
Why?
|
Rural Population | 2 | 2022 | 136 | 0.210 |
Why?
|
Erythrocyte Transfusion | 1 | 2023 | 60 | 0.210 |
Why?
|
Hyperaldosteronism | 2 | 2018 | 13 | 0.210 |
Why?
|
Paternalism | 3 | 2012 | 24 | 0.210 |
Why?
|
Perioperative Care | 2 | 2014 | 161 | 0.210 |
Why?
|
Pain Management | 2 | 2021 | 127 | 0.210 |
Why?
|
Blood Transfusion | 1 | 2023 | 157 | 0.210 |
Why?
|
Predictive Value of Tests | 6 | 2017 | 1673 | 0.210 |
Why?
|
Students, Medical | 2 | 2013 | 384 | 0.210 |
Why?
|
Frailty | 1 | 2023 | 58 | 0.210 |
Why?
|
Language | 1 | 2023 | 151 | 0.210 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2022 | 74 | 0.200 |
Why?
|
Head Injuries, Penetrating | 1 | 2022 | 54 | 0.200 |
Why?
|
Resuscitation | 2 | 2022 | 100 | 0.200 |
Why?
|
Follow-Up Studies | 6 | 2016 | 3640 | 0.200 |
Why?
|
Planning Techniques | 1 | 2020 | 10 | 0.200 |
Why?
|
Vascular Neoplasms | 1 | 2021 | 19 | 0.200 |
Why?
|
Philosophy, Medical | 1 | 2001 | 17 | 0.200 |
Why?
|
Risk Adjustment | 2 | 2018 | 39 | 0.190 |
Why?
|
Quality-Adjusted Life Years | 2 | 2020 | 138 | 0.190 |
Why?
|
Episode of Care | 1 | 2020 | 7 | 0.190 |
Why?
|
Jugular Veins | 1 | 2021 | 69 | 0.190 |
Why?
|
Social Problems | 1 | 2020 | 10 | 0.190 |
Why?
|
Specialty Boards | 1 | 2020 | 24 | 0.190 |
Why?
|
Nuclear Medicine | 1 | 2020 | 12 | 0.190 |
Why?
|
Endocrine Surgical Procedures | 1 | 2020 | 3 | 0.190 |
Why?
|
Brain Injuries, Traumatic | 1 | 2022 | 86 | 0.190 |
Why?
|
Octreotide | 1 | 2020 | 16 | 0.190 |
Why?
|
Coordination Complexes | 1 | 2020 | 19 | 0.190 |
Why?
|
Fee-for-Service Plans | 1 | 2020 | 30 | 0.190 |
Why?
|
Republic of Korea | 2 | 2021 | 31 | 0.190 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2022 | 139 | 0.190 |
Why?
|
Mental Competency | 2 | 2018 | 49 | 0.190 |
Why?
|
Accreditation | 1 | 2020 | 60 | 0.190 |
Why?
|
Obesity, Morbid | 2 | 2016 | 225 | 0.190 |
Why?
|
SEER Program | 6 | 2019 | 190 | 0.190 |
Why?
|
Operative Time | 1 | 2020 | 127 | 0.190 |
Why?
|
Epidemics | 1 | 2020 | 33 | 0.190 |
Why?
|
Neurologic Examination | 2 | 2012 | 118 | 0.180 |
Why?
|
Models, Economic | 1 | 2020 | 60 | 0.180 |
Why?
|
Ophthalmology | 1 | 2020 | 39 | 0.180 |
Why?
|
Markov Chains | 1 | 2020 | 125 | 0.180 |
Why?
|
Gender Identity | 1 | 2020 | 52 | 0.180 |
Why?
|
ras Proteins | 1 | 2020 | 128 | 0.180 |
Why?
|
Hospital Costs | 1 | 2020 | 105 | 0.180 |
Why?
|
Otolaryngology | 1 | 2020 | 53 | 0.180 |
Why?
|
Ethics Committees, Research | 2 | 2018 | 33 | 0.180 |
Why?
|
Insurance Coverage | 1 | 2020 | 117 | 0.180 |
Why?
|
Medicare | 2 | 2020 | 410 | 0.180 |
Why?
|
Disease Transmission, Infectious | 1 | 2020 | 57 | 0.180 |
Why?
|
Case-Control Studies | 6 | 2019 | 1805 | 0.180 |
Why?
|
Health Resources | 1 | 2020 | 76 | 0.170 |
Why?
|
Radionuclide Imaging | 3 | 2014 | 220 | 0.170 |
Why?
|
Product Recalls and Withdrawals | 1 | 2019 | 2 | 0.170 |
Why?
|
Time-to-Treatment | 1 | 2020 | 98 | 0.170 |
Why?
|
Radiology | 1 | 2021 | 194 | 0.170 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2020 | 93 | 0.170 |
Why?
|
Infusions, Intra-Arterial | 1 | 2019 | 34 | 0.170 |
Why?
|
Renal Dialysis | 2 | 2014 | 355 | 0.170 |
Why?
|
Infusion Pumps, Implantable | 1 | 2019 | 25 | 0.170 |
Why?
|
Clinical Chemistry Tests | 1 | 2019 | 11 | 0.170 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2019 | 18 | 0.170 |
Why?
|
Goiter, Substernal | 1 | 2018 | 3 | 0.170 |
Why?
|
Calcium Gluconate | 1 | 2018 | 3 | 0.170 |
Why?
|
Interdisciplinary Communication | 2 | 2018 | 130 | 0.170 |
Why?
|
Chicago | 5 | 2020 | 1379 | 0.170 |
Why?
|
Immunoassay | 1 | 2019 | 92 | 0.170 |
Why?
|
False Negative Reactions | 2 | 2018 | 63 | 0.170 |
Why?
|
Hepatic Artery | 1 | 2019 | 83 | 0.170 |
Why?
|
Racism | 1 | 2020 | 81 | 0.160 |
Why?
|
Liability, Legal | 2 | 2009 | 32 | 0.160 |
Why?
|
Child | 9 | 2022 | 6927 | 0.160 |
Why?
|
Workflow | 1 | 2018 | 77 | 0.160 |
Why?
|
Violence | 1 | 2020 | 143 | 0.160 |
Why?
|
Liver Neoplasms | 2 | 2021 | 736 | 0.160 |
Why?
|
Health Personnel | 1 | 2020 | 202 | 0.160 |
Why?
|
Social Justice | 2 | 2018 | 49 | 0.160 |
Why?
|
Venous Thrombosis | 1 | 2021 | 243 | 0.160 |
Why?
|
Ablation Techniques | 1 | 2018 | 34 | 0.160 |
Why?
|
Laryngoplasty | 1 | 2017 | 5 | 0.160 |
Why?
|
Suction | 2 | 2008 | 35 | 0.160 |
Why?
|
Diagnosis, Differential | 2 | 2015 | 1565 | 0.160 |
Why?
|
Calcitriol | 1 | 2018 | 174 | 0.160 |
Why?
|
Antineoplastic Agents | 2 | 2006 | 2360 | 0.160 |
Why?
|
Computer Simulation | 2 | 2020 | 1078 | 0.150 |
Why?
|
Medical Overuse | 1 | 2017 | 36 | 0.150 |
Why?
|
MicroRNAs | 1 | 2022 | 534 | 0.150 |
Why?
|
Multitasking Behavior | 1 | 2017 | 1 | 0.150 |
Why?
|
Vesicovaginal Fistula | 1 | 2017 | 12 | 0.150 |
Why?
|
Reoperation | 2 | 2017 | 597 | 0.150 |
Why?
|
Stomach Neoplasms | 1 | 2020 | 266 | 0.150 |
Why?
|
Global Health | 2 | 2016 | 193 | 0.150 |
Why?
|
Social Perception | 1 | 2018 | 95 | 0.150 |
Why?
|
Empathy | 2 | 2010 | 147 | 0.150 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2021 | 384 | 0.150 |
Why?
|
Abscess | 1 | 1997 | 91 | 0.150 |
Why?
|
Age Factors | 6 | 2019 | 1851 | 0.150 |
Why?
|
Travel | 1 | 2017 | 68 | 0.150 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 413 | 0.140 |
Why?
|
Electrosurgery | 1 | 2016 | 9 | 0.140 |
Why?
|
Ultrasonic Surgical Procedures | 1 | 2016 | 5 | 0.140 |
Why?
|
Adrenal Glands | 2 | 2009 | 76 | 0.140 |
Why?
|
Health Care Surveys | 1 | 2017 | 278 | 0.140 |
Why?
|
Transcriptome | 1 | 2020 | 580 | 0.140 |
Why?
|
Hirschsprung Disease | 1 | 2016 | 11 | 0.140 |
Why?
|
Hypertension | 2 | 2018 | 1141 | 0.140 |
Why?
|
Contracts | 1 | 2015 | 2 | 0.140 |
Why?
|
Psychometrics | 1 | 2017 | 327 | 0.140 |
Why?
|
Awareness | 1 | 2016 | 93 | 0.140 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2017 | 108 | 0.140 |
Why?
|
Disability Evaluation | 1 | 2016 | 136 | 0.140 |
Why?
|
Databases, Factual | 3 | 2019 | 814 | 0.140 |
Why?
|
Lymphadenopathy | 1 | 2015 | 17 | 0.130 |
Why?
|
Professional Competence | 1 | 2016 | 68 | 0.130 |
Why?
|
Biomarkers, Tumor | 3 | 2016 | 1464 | 0.130 |
Why?
|
Gynecology | 1 | 2017 | 124 | 0.130 |
Why?
|
Third-Party Consent | 1 | 2015 | 24 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 1197 | 0.130 |
Why?
|
Gastric Bypass | 1 | 2016 | 110 | 0.130 |
Why?
|
Choristoma | 1 | 2015 | 68 | 0.130 |
Why?
|
Epigenomics | 1 | 2016 | 100 | 0.130 |
Why?
|
Clinical Protocols | 1 | 2015 | 156 | 0.130 |
Why?
|
Hospitals | 1 | 2018 | 294 | 0.130 |
Why?
|
Hyperparathyroidism | 2 | 2007 | 67 | 0.130 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 51 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 5 | 2018 | 2601 | 0.130 |
Why?
|
Spirituality | 1 | 2015 | 87 | 0.130 |
Why?
|
Heart-Assist Devices | 1 | 2022 | 731 | 0.130 |
Why?
|
Scotland | 1 | 2014 | 6 | 0.130 |
Why?
|
Biological Assay | 1 | 2014 | 78 | 0.130 |
Why?
|
Creativity | 1 | 2014 | 10 | 0.130 |
Why?
|
History, 18th Century | 1 | 2014 | 23 | 0.130 |
Why?
|
Digestive System Surgical Procedures | 1 | 2016 | 120 | 0.120 |
Why?
|
Survival Analysis | 3 | 2021 | 1538 | 0.120 |
Why?
|
Bioethical Issues | 1 | 2014 | 38 | 0.120 |
Why?
|
Cause of Death | 1 | 2015 | 277 | 0.120 |
Why?
|
Mass Screening | 1 | 2018 | 618 | 0.120 |
Why?
|
Health Policy | 3 | 2020 | 180 | 0.120 |
Why?
|
Patient Readmission | 1 | 2017 | 329 | 0.120 |
Why?
|
Cisplatin | 2 | 2006 | 612 | 0.120 |
Why?
|
Canada | 3 | 2015 | 204 | 0.120 |
Why?
|
Voice Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
Family | 1 | 2015 | 311 | 0.110 |
Why?
|
Voice Quality | 1 | 2013 | 11 | 0.110 |
Why?
|
Health Status | 1 | 2015 | 360 | 0.110 |
Why?
|
Research Design | 1 | 2017 | 594 | 0.110 |
Why?
|
Genetic Variation | 1 | 2020 | 1351 | 0.110 |
Why?
|
Muscle, Skeletal | 1 | 2016 | 449 | 0.110 |
Why?
|
Hematoma | 1 | 2013 | 104 | 0.110 |
Why?
|
Aged, 80 and over | 7 | 2020 | 6509 | 0.110 |
Why?
|
Length of Stay | 5 | 2018 | 702 | 0.110 |
Why?
|
Sex Factors | 4 | 2019 | 1054 | 0.110 |
Why?
|
Attention | 1 | 2016 | 388 | 0.100 |
Why?
|
Aging | 1 | 2016 | 691 | 0.100 |
Why?
|
Adolescent | 8 | 2021 | 8981 | 0.100 |
Why?
|
Endoscopy | 1 | 2015 | 332 | 0.100 |
Why?
|
Time Factors | 6 | 2016 | 5210 | 0.100 |
Why?
|
Referral and Consultation | 1 | 2014 | 328 | 0.100 |
Why?
|
Electromyography | 1 | 2012 | 183 | 0.100 |
Why?
|
Young Adult | 7 | 2019 | 5976 | 0.100 |
Why?
|
DNA Methylation | 1 | 2016 | 628 | 0.100 |
Why?
|
Pancreaticoduodenectomy | 2 | 2004 | 81 | 0.100 |
Why?
|
Esophagectomy | 2 | 2004 | 84 | 0.100 |
Why?
|
Liver | 1 | 2016 | 1230 | 0.100 |
Why?
|
Lymph Node Excision | 3 | 2017 | 217 | 0.100 |
Why?
|
Liver Failure, Acute | 1 | 2011 | 38 | 0.100 |
Why?
|
Multivariate Analysis | 4 | 2019 | 999 | 0.100 |
Why?
|
Right to Die | 1 | 2010 | 12 | 0.100 |
Why?
|
Diagnostic Imaging | 3 | 2021 | 469 | 0.100 |
Why?
|
Jurisprudence | 1 | 2010 | 25 | 0.100 |
Why?
|
Vacuum Extraction, Obstetrical | 1 | 2010 | 6 | 0.100 |
Why?
|
Biomedical Technology | 1 | 2010 | 20 | 0.090 |
Why?
|
Capital Punishment | 1 | 2010 | 3 | 0.090 |
Why?
|
Adenoids | 1 | 2009 | 9 | 0.090 |
Why?
|
Nuclear Reactors | 1 | 2009 | 8 | 0.090 |
Why?
|
Craniocerebral Trauma | 1 | 2010 | 52 | 0.090 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2010 | 28 | 0.090 |
Why?
|
Palatine Tonsil | 1 | 2009 | 30 | 0.090 |
Why?
|
Scalp | 1 | 2010 | 72 | 0.090 |
Why?
|
Safety | 1 | 2010 | 152 | 0.090 |
Why?
|
Odds Ratio | 1 | 2012 | 678 | 0.090 |
Why?
|
Mutation | 4 | 2022 | 3968 | 0.090 |
Why?
|
Ethics | 1 | 2009 | 24 | 0.090 |
Why?
|
Prisoners | 1 | 2010 | 40 | 0.090 |
Why?
|
Education, Medical, Continuing | 1 | 2010 | 107 | 0.090 |
Why?
|
Specialization | 2 | 2008 | 65 | 0.090 |
Why?
|
Data Collection | 3 | 2000 | 372 | 0.090 |
Why?
|
Laparotomy | 1 | 2009 | 59 | 0.090 |
Why?
|
China | 1 | 2010 | 228 | 0.090 |
Why?
|
Neural Conduction | 1 | 2009 | 69 | 0.090 |
Why?
|
Propensity Score | 2 | 2021 | 136 | 0.080 |
Why?
|
Medicine | 2 | 2008 | 89 | 0.080 |
Why?
|
Medical Staff, Hospital | 2 | 2000 | 107 | 0.080 |
Why?
|
Infusions, Intravenous | 2 | 2020 | 429 | 0.080 |
Why?
|
Hemorrhage | 1 | 2010 | 268 | 0.080 |
Why?
|
Genome-Wide Association Study | 1 | 2016 | 1621 | 0.080 |
Why?
|
Philosophy | 1 | 2008 | 9 | 0.080 |
Why?
|
Colectomy | 1 | 2009 | 167 | 0.080 |
Why?
|
Prospective Studies | 4 | 2024 | 4213 | 0.080 |
Why?
|
Cardiopulmonary Resuscitation | 1 | 2010 | 190 | 0.080 |
Why?
|
Professional Practice | 1 | 2008 | 46 | 0.080 |
Why?
|
Registries | 3 | 2021 | 702 | 0.080 |
Why?
|
Intraoperative Period | 2 | 2019 | 90 | 0.070 |
Why?
|
Pre-Eclampsia | 1 | 2010 | 246 | 0.070 |
Why?
|
Health Services Accessibility | 2 | 2017 | 394 | 0.070 |
Why?
|
Comorbidity | 2 | 2023 | 943 | 0.070 |
Why?
|
Intestinal Obstruction | 1 | 2007 | 88 | 0.070 |
Why?
|
Biomarkers | 2 | 2018 | 1718 | 0.070 |
Why?
|
Matched-Pair Analysis | 1 | 2006 | 43 | 0.070 |
Why?
|
Bariatric Surgery | 1 | 2008 | 194 | 0.070 |
Why?
|
Neck | 3 | 2015 | 100 | 0.070 |
Why?
|
Positron-Emission Tomography | 2 | 2020 | 329 | 0.070 |
Why?
|
Virtues | 1 | 2005 | 12 | 0.070 |
Why?
|
Thiazolidinediones | 1 | 2006 | 82 | 0.070 |
Why?
|
Cetuximab | 1 | 2006 | 113 | 0.070 |
Why?
|
Government Regulation | 1 | 2005 | 49 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 1 | 2014 | 2271 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2006 | 160 | 0.060 |
Why?
|
Qualitative Research | 2 | 2018 | 256 | 0.060 |
Why?
|
Doxorubicin | 1 | 2006 | 295 | 0.060 |
Why?
|
Advisory Committees | 2 | 2018 | 90 | 0.060 |
Why?
|
Models, Theoretical | 1 | 2008 | 482 | 0.060 |
Why?
|
Disease-Free Survival | 2 | 2019 | 1204 | 0.060 |
Why?
|
Kidney Transplantation | 2 | 2009 | 849 | 0.060 |
Why?
|
Arizona | 1 | 2004 | 10 | 0.060 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 1991 | 0.060 |
Why?
|
Deoxycytidine | 1 | 2006 | 237 | 0.060 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 154 | 0.060 |
Why?
|
Endothelium, Corneal | 2 | 1995 | 19 | 0.060 |
Why?
|
Gift Giving | 1 | 2004 | 5 | 0.060 |
Why?
|
Cross-Sectional Studies | 2 | 2020 | 1621 | 0.060 |
Why?
|
Ethical Theory | 1 | 2004 | 10 | 0.060 |
Why?
|
Paclitaxel | 1 | 2006 | 460 | 0.060 |
Why?
|
Logistic Models | 2 | 2019 | 1186 | 0.060 |
Why?
|
Sodium-Potassium-Exchanging ATPase | 2 | 1995 | 78 | 0.060 |
Why?
|
North America | 2 | 2018 | 180 | 0.060 |
Why?
|
Genetic Therapy | 1 | 2006 | 342 | 0.060 |
Why?
|
Altruism | 1 | 2004 | 35 | 0.060 |
Why?
|
Indocyanine Green | 1 | 2023 | 22 | 0.060 |
Why?
|
Transplants | 1 | 2003 | 40 | 0.060 |
Why?
|
Deception | 1 | 2003 | 20 | 0.060 |
Why?
|
Liver Transplantation | 1 | 2011 | 1268 | 0.050 |
Why?
|
Health Care Rationing | 1 | 2003 | 83 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2003 | 80 | 0.050 |
Why?
|
Head | 1 | 2023 | 132 | 0.050 |
Why?
|
Optical Imaging | 1 | 2023 | 48 | 0.050 |
Why?
|
Latin America | 1 | 2021 | 14 | 0.050 |
Why?
|
Pyridones | 1 | 2022 | 51 | 0.050 |
Why?
|
Research | 1 | 2003 | 253 | 0.050 |
Why?
|
Thyroglobulin | 1 | 2002 | 59 | 0.050 |
Why?
|
Adenoma, Islet Cell | 1 | 2001 | 28 | 0.050 |
Why?
|
Spinal Fusion | 1 | 2002 | 85 | 0.050 |
Why?
|
Mental Health | 1 | 2003 | 162 | 0.050 |
Why?
|
Lumbar Vertebrae | 1 | 2002 | 148 | 0.050 |
Why?
|
Appendicitis | 1 | 2002 | 62 | 0.050 |
Why?
|
Carcinoid Tumor | 1 | 2001 | 42 | 0.050 |
Why?
|
Algorithms | 3 | 2018 | 1830 | 0.050 |
Why?
|
Ultrasonography, Interventional | 1 | 2021 | 121 | 0.050 |
Why?
|
Imidazoles | 1 | 2022 | 162 | 0.050 |
Why?
|
Chemoembolization, Therapeutic | 1 | 2001 | 36 | 0.050 |
Why?
|
Immunoglobulin G | 1 | 2023 | 456 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 2 | 2013 | 860 | 0.050 |
Why?
|
Models, Organizational | 1 | 2001 | 46 | 0.050 |
Why?
|
Salivary Glands | 1 | 2020 | 18 | 0.050 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2001 | 106 | 0.050 |
Why?
|
Patient Advocacy | 1 | 2001 | 49 | 0.050 |
Why?
|
Suicide, Assisted | 1 | 2001 | 31 | 0.050 |
Why?
|
Morbidity | 1 | 2001 | 148 | 0.050 |
Why?
|
Reimbursement Mechanisms | 1 | 2020 | 41 | 0.050 |
Why?
|
Policy Making | 1 | 2020 | 62 | 0.050 |
Why?
|
Hepatectomy | 1 | 2001 | 166 | 0.050 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2006 | 930 | 0.050 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 261 | 0.050 |
Why?
|
Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 56 | 0.050 |
Why?
|
Neurosurgical Procedures | 1 | 2022 | 213 | 0.050 |
Why?
|
Uncertainty | 1 | 2020 | 71 | 0.050 |
Why?
|
Bias | 1 | 2020 | 127 | 0.050 |
Why?
|
Efficiency, Organizational | 1 | 2020 | 58 | 0.050 |
Why?
|
Cholecystitis | 1 | 1999 | 15 | 0.050 |
Why?
|
Costs and Cost Analysis | 2 | 2013 | 153 | 0.040 |
Why?
|
Antibodies, Monoclonal | 1 | 2006 | 1376 | 0.040 |
Why?
|
Body Mass Index | 2 | 2016 | 770 | 0.040 |
Why?
|
Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 3 | 0.040 |
Why?
|
Postoperative Period | 1 | 2020 | 303 | 0.040 |
Why?
|
Organometallic Compounds | 1 | 2020 | 132 | 0.040 |
Why?
|
Meta-Analysis as Topic | 1 | 2019 | 87 | 0.040 |
Why?
|
Tracheomalacia | 1 | 2018 | 2 | 0.040 |
Why?
|
Anesthesia, Endotracheal | 1 | 2018 | 6 | 0.040 |
Why?
|
Cholecystectomy, Laparoscopic | 1 | 1999 | 50 | 0.040 |
Why?
|
Medical Audit | 1 | 1999 | 41 | 0.040 |
Why?
|
Adrenocortical Adenoma | 1 | 1998 | 2 | 0.040 |
Why?
|
Ethics, Professional | 1 | 2018 | 10 | 0.040 |
Why?
|
Pain, Postoperative | 1 | 2021 | 240 | 0.040 |
Why?
|
Publication Bias | 1 | 2018 | 13 | 0.040 |
Why?
|
Cross Infection | 1 | 2020 | 141 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2021 | 233 | 0.040 |
Why?
|
Hypokalemia | 1 | 2018 | 29 | 0.040 |
Why?
|
Delphi Technique | 1 | 2018 | 80 | 0.040 |
Why?
|
Multidetector Computed Tomography | 1 | 2019 | 54 | 0.040 |
Why?
|
Ethics Consultation | 1 | 2018 | 12 | 0.040 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 1998 | 18 | 0.040 |
Why?
|
Tracheostomy | 1 | 2018 | 42 | 0.040 |
Why?
|
Publications | 1 | 2018 | 27 | 0.040 |
Why?
|
Pneumothorax | 1 | 2018 | 52 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 916 | 0.040 |
Why?
|
Urban Population | 1 | 2019 | 213 | 0.040 |
Why?
|
Infant, Newborn | 3 | 2016 | 2379 | 0.040 |
Why?
|
Injections | 1 | 2017 | 109 | 0.040 |
Why?
|
Intubation, Intratracheal | 1 | 2018 | 144 | 0.040 |
Why?
|
Reproducibility of Results | 1 | 2023 | 2705 | 0.040 |
Why?
|
Pilot Projects | 1 | 1999 | 839 | 0.040 |
Why?
|
Organizational Policy | 2 | 2011 | 55 | 0.040 |
Why?
|
Body Temperature | 1 | 2016 | 124 | 0.030 |
Why?
|
Tissue Donors | 2 | 2013 | 463 | 0.030 |
Why?
|
Tamoxifen | 1 | 1996 | 168 | 0.030 |
Why?
|
CpG Islands | 1 | 2016 | 151 | 0.030 |
Why?
|
Pancreatic Polypeptide | 1 | 2015 | 9 | 0.030 |
Why?
|
Chromogranin A | 1 | 2015 | 8 | 0.030 |
Why?
|
Sleep Apnea, Obstructive | 1 | 2018 | 219 | 0.030 |
Why?
|
Goals | 1 | 2016 | 67 | 0.030 |
Why?
|
Calcitonin | 1 | 2015 | 38 | 0.030 |
Why?
|
Reference Values | 1 | 2016 | 674 | 0.030 |
Why?
|
Mannitol | 1 | 1995 | 49 | 0.030 |
Why?
|
Ki-67 Antigen | 1 | 2015 | 64 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 3362 | 0.030 |
Why?
|
Tertiary Care Centers | 1 | 2015 | 94 | 0.030 |
Why?
|
Phenotype | 1 | 2021 | 2378 | 0.030 |
Why?
|
Age of Onset | 1 | 2015 | 310 | 0.030 |
Why?
|
Finland | 1 | 2014 | 29 | 0.030 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 1384 | 0.030 |
Why?
|
Swine | 1 | 2016 | 555 | 0.030 |
Why?
|
Frozen Sections | 1 | 2014 | 48 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2015 | 204 | 0.030 |
Why?
|
Linear Models | 1 | 2015 | 421 | 0.030 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 220 | 0.030 |
Why?
|
Netherlands | 1 | 2013 | 19 | 0.030 |
Why?
|
Glucose | 2 | 1995 | 638 | 0.030 |
Why?
|
Codes of Ethics | 1 | 2013 | 12 | 0.030 |
Why?
|
Ca(2+) Mg(2+)-ATPase | 1 | 1993 | 1 | 0.030 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2018 | 350 | 0.030 |
Why?
|
Cell Differentiation | 1 | 2020 | 1458 | 0.030 |
Why?
|
Warfare | 1 | 2013 | 10 | 0.030 |
Why?
|
Investments | 1 | 2013 | 6 | 0.030 |
Why?
|
Retirement | 1 | 2013 | 10 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2013 | 44 | 0.030 |
Why?
|
Regression Analysis | 1 | 2014 | 596 | 0.030 |
Why?
|
Proxy | 1 | 2013 | 24 | 0.030 |
Why?
|
Disasters | 1 | 2013 | 20 | 0.030 |
Why?
|
Child, Preschool | 2 | 2010 | 3612 | 0.030 |
Why?
|
Pregnancy | 2 | 2010 | 2894 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2014 | 912 | 0.030 |
Why?
|
Death | 1 | 2013 | 73 | 0.030 |
Why?
|
Muscle Weakness | 1 | 2012 | 61 | 0.030 |
Why?
|
Cost of Illness | 1 | 2013 | 150 | 0.030 |
Why?
|
ROC Curve | 1 | 2014 | 752 | 0.030 |
Why?
|
Workload | 1 | 2013 | 128 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2438 | 0.030 |
Why?
|
Financial Support | 1 | 2011 | 7 | 0.030 |
Why?
|
Fatigue | 1 | 2012 | 174 | 0.030 |
Why?
|
Recurrence | 1 | 2014 | 1139 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2012 | 137 | 0.030 |
Why?
|
Prevalence | 1 | 2015 | 1239 | 0.020 |
Why?
|
DNA | 2 | 1995 | 1294 | 0.020 |
Why?
|
Education, Medical, Undergraduate | 1 | 2013 | 160 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2014 | 1753 | 0.020 |
Why?
|
Pregnancy in Diabetics | 1 | 2010 | 37 | 0.020 |
Why?
|
Fatal Outcome | 1 | 2010 | 293 | 0.020 |
Why?
|
Kidney Calculi | 1 | 2012 | 339 | 0.020 |
Why?
|
Depression | 1 | 2012 | 473 | 0.020 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2016 | 2357 | 0.020 |
Why?
|
Parents | 1 | 2010 | 272 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2009 | 751 | 0.020 |
Why?
|
Weight Loss | 1 | 2008 | 229 | 0.020 |
Why?
|
Naphthalenes | 1 | 2006 | 45 | 0.020 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2006 | 59 | 0.020 |
Why?
|
Culture Media | 2 | 1995 | 147 | 0.020 |
Why?
|
Cattle | 2 | 1995 | 376 | 0.010 |
Why?
|
Cadaver | 1 | 2004 | 185 | 0.010 |
Why?
|
Resource Allocation | 1 | 2004 | 65 | 0.010 |
Why?
|
Intervertebral Disc Displacement | 1 | 2002 | 24 | 0.010 |
Why?
|
Animals | 3 | 2016 | 26582 | 0.010 |
Why?
|
Cell Membrane | 2 | 1995 | 666 | 0.010 |
Why?
|
Gangrene | 1 | 1999 | 7 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1995 | 2818 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2001 | 1686 | 0.010 |
Why?
|
Acute Disease | 1 | 1999 | 826 | 0.010 |
Why?
|
Osmolar Concentration | 1 | 1995 | 181 | 0.010 |
Why?
|
Remission Induction | 1 | 1996 | 722 | 0.010 |
Why?
|
DNA Damage | 1 | 1993 | 366 | 0.010 |
Why?
|
Infant, Premature | 1 | 1952 | 290 | 0.010 |
Why?
|
Infant | 1 | 1952 | 3046 | 0.000 |
Why?
|